Metagenomi, Inc. (MGX)
(Delayed Data from NSDQ)
$2.75 USD
+0.01 (0.36%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $2.74 -0.01 (-0.36%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MGX 2.75 +0.01(0.36%)
Will MGX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MGX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for MGX
Mount Gibson Iron Ramps Up Share Buy-Back
BlackRock, Microsoft, Others Team Up For $30B Artificial Intelligence Fund: Help US Fuel 'AI Innovation And Economic Growth'
Mount Gibson Updates Share Buy-Back Details
Buy Rating Justified by Metagenomi’s Promising Gene Therapy and Strategic Market Positioning in Hemophilia A Treatment
Buy Rating Justified by Metagenomi’s Breakthrough in Long-term Gene Therapy Efficacy and Safety